BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27055469)

  • 1. CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).
    Makinen SR; Zhu Q; Davis HL; Weeratna RD
    Int Immunol; 2016 Sep; 28(9):453-61. PubMed ID: 27055469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants.
    Qiu Q; Wang RY; Jiao X; Jin B; Sugauchi F; Grandinetti T; Alter HJ; Shih JW
    Vaccine; 2008 Oct; 26(43):5527-5534. PubMed ID: 18675871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.
    Kumar S; Jones TR; Oakley MS; Zheng H; Kuppusamy SP; Taye A; Krieg AM; Stowers AW; Kaslow DC; Hoffman SL
    Infect Immun; 2004 Feb; 72(2):949-57. PubMed ID: 14742540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines.
    Fox CB; Baldwin SL; Vedvick TS; Angov E; Reed SG
    Clin Vaccine Immunol; 2012 Oct; 19(10):1633-40. PubMed ID: 22896687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
    Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
    Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative assessment of humoral immune responses of aluminum hydroxide and oil-emulsion adjuvants in Influenza (H9N2) and Newcastle inactive vaccines to chickens.
    Jafari M; Moghaddam Pour M; Taghizadeh M; Masoudi S; Bayat Z
    Artif Cells Nanomed Biotechnol; 2017 Feb; 45(1):84-89. PubMed ID: 26757848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
    Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
    Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
    Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
    J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG oligodeoxynucleotide and montanide ISA 206 adjuvant combination augments the immune responses of a recombinant FMDV vaccine in cattle.
    Ren J; Yang L; Xu H; Zhang Y; Wan M; Liu G; Zhao L; Wang L; Yu Y
    Vaccine; 2011 Oct; 29(45):7960-5. PubMed ID: 21872635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
    Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A
    Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates.
    Wille-Reece U; Flynn BJ; Loré K; Koup RA; Miles AP; Saul A; Kedl RM; Mattapallil JJ; Weiss WR; Roederer M; Seder RA
    J Exp Med; 2006 May; 203(5):1249-58. PubMed ID: 16636134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity.
    Song YC; Cheng HY; Leng CH; Chiang SK; Lin CW; Chong P; Huang MH; Liu SJ
    J Control Release; 2014 Jan; 173():158-65. PubMed ID: 24177312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4
    Melssen MM; Fisher CT; Slingluff CL; Melief CJM
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36939214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-18, and IFN-γ.
    Desbien AL; Reed SJ; Bailor HR; Dubois Cauwelaert N; Laurance JD; Orr MT; Fox CB; Carter D; Reed SG; Duthie MS
    Eur J Immunol; 2015 Feb; 45(2):407-17. PubMed ID: 25367751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemically administered gp100 encoding DNA vaccine for melanoma using water-in-oil-in-water multiple emulsion delivery systems.
    Kalariya M; Amiji MM
    Int J Pharm; 2013 Sep; 453(2):400-7. PubMed ID: 23702000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway.
    Kim EH; Woodruff MC; Grigoryan L; Maier B; Lee SH; Mandal P; Cortese M; Natrajan MS; Ravindran R; Ma H; Merad M; Gitlin AD; Mocarski ES; Jacob J; Pulendran B
    Elife; 2020 Jun; 9():. PubMed ID: 32515732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
    Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
    Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer.
    Habjanec L; Halassy B; Tomasić J
    Int Immunopharmacol; 2008 May; 8(5):717-24. PubMed ID: 18387514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits.
    Halassy B; Vdović V; Habjanec L; Balija ML; Gebauer B; Sabioncello A; Santek T; Tomasić J
    Vaccine; 2007 Apr; 25(17):3475-81. PubMed ID: 17239503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.